Kumaraguru Veerasamy

xeraya capital life sciences coronavirus covid-19 venture capital esg ai crispr private equity biotechnology healthcare xerayacapital circular economy vaccines fda gene therapy antibiotics medical technology gram negative bacteria allecra pharmaceutical biomedical sustainable financing impact investing renewable resources green economy glycoproteomics emergency use authorization mrna vaccine oxford astrazeneca clinical trial vaccine production mrna vaccine mab monoclonal antibodies pandemic machine learning artificial intelligence human microbiome microbiome adult leukemia stem cells drug approvals talen gene editing genome bacteria liquidia nanotechnology 3d printing eric lefkofsky elon musk serial entrepreneurs entrepreneurship tobacco smoking cessation chrono therapeutics plasma derivatives preparative electrophoresis chromatography plasma separation blood plasma drug resistant bacteria carbon offset carbon credit climate change #carbon exchange cannabis sativa cbd thc cannabis legal status pain control cannabis pharma medical marijuana cannabis gmo nitrogen fixation malnutrition world hunger food security companion diagnostics adenoma tumor detection cancer analytes non-invasive biopsy liquid biopsy transplantation sclerosis diabetes regenerative medicine cord blood progenitor cells green investment msci sustainable investment sustainable development ri sri zfn cancer immunotherapy genome engineering genome editing augmented reality virtual reality telehealth telemedicine digital healthcare digital health renewable energy specialty chemicals renewable chemicals high blood pressure pah pulmonary hypertension pulmonary arterial hypertension equity financing raise capital financing rounds funding rounds financing series healthcare technology deep learning genomics analysis rtificial intelligence sovereign wealth fund swf rna technologies vaccination antiviral drugs treatment therapeutics immunization covid19 gene control gene expression epigenetic therapies epigenetic pathways epigenetics biontech pfizer moderna inclusive vaccines iva cepi post marketing drug discovery nda ind animal testing new drugs drug testing immunogenicity vaccine manufacturing immune response b-cell t-cell recombinant vector vaccine dna plasmid vaccine herd immunity vaccine platforms rna drugs immunomodulatory agents cytokine release syndrome cytokine storm elisa dna test rna test immunology assay antibody assay isothermal amplification rt-pcr diagnostics socio economic impact mortality rate healthcare system public policies who severe acute respiratory syndrome sars mers diagnosis bio ethanol jet fuel bio fuels capture carbon recycle carbon lanzatech corporate venture capital cvc google ventures ge ventures qualcomm ventures health microbiota symbiosis hospital acquired pneumonia urinary tract infection hospital acquired infections medicine bone marrow disease blood disease imago bio oncomyx acute myeloid leukemia aml socially responsible investment responsible investment governance social environment bone marrow transplant market study cell therapy novel drugs drug therapy cder nonalcoholic fatty liver disease nafld nash data analytics data sharing 2019 trends industry report genetic engineering zinc finger cas9 medical devices prime biologics dna rna bacteria defense crispr cas bacteriophages #xerayacapital primebiologics agriculture industry investment medical factsnfigures innovation